PDCD1 and cancer: Thus, humanized anti-PD-1 antibodies, including pembrolizumab, have been developed and were approved as immune checkpoint inhibitor treatments for several cancers, including unresectable and metastatic malignant melanoma, non-small cell lung cancer, unresectable urothelial cancer, and refractory non-Hodgkin lymphoma [12–14].